glofitamab,Obinutuzumab 
roche
['lymsm', 'glofitamab', 'car t']
glofitamab in pts with r/r lbcl
phase 2, n=107, 35% post car t
orr/cr: 50%/35%
cr rates (post car t/no prior car t): 32%/37%
crs: mostly gr 1-51%, gr 2-12%, gr 3-3%, gr 4-2%
promising option especially post-car t #asco22 #lymsm 
Hematology and Oncology Fellow @MDAndersonNews
Interest in hematological malignancies | Tweets/opinions are mine ? medical advice.